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Structure-Based Computational Database Screening,
In Vitro Assay, and NMR Assessment of Compounds
that Target TAR RNA
3D protein structures were approved for clinical use
[4], yet there has been little reported research on drug
discovery using unique 3D RNA structures [5, 6]. Un-
doubtedly, this neglect has been due to the relative
paucity of RNA structures. However, the number of RNA
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4 Howard Hughes Medical Institute structures is increasing, and some of them represent
potential targets for the design of new drugs.University of California
San Francisco, California 94143 Our goal is to develop a method to discover novel
non-peptide, non-nucleotide compounds that interact
with high affinity and specificity with a single RNA site.
These compounds should also represent promisingSummary
scaffolds for subsequent chemical modification that
would enhance their pharmaceutical properties. OneThere has been little prior effort to discover new drugs
way to find such promising lead compounds is to screenon the basis of a unique RNA structure. Binding of the
the Available Chemicals Directory (ACD) or a corporateviral transactivator Tat to the 5 bulge of the transacti-
library of compounds. These typically comprise 105–106vation response (TAR) element is necessary for HIV-1
compounds. Currently, high-throughput screening assaysreplication, so TAR RNA is a superb target. A computa-
are set up at enormous expense to monitor experimen-tional approach was developed to screen a large
tally the binding of compounds. However, several recentchemical library for binding to a three-dimensional
improvements in computational docking methodologiesRNA structure. Scoring function development, flexible
permit effective screening of compounds in silico. Inligand docking, and limited target flexibility were es-
particular, our inclusion of solvation effects for pre-sential. From the ranked list of compounds predicted
dicting accurate binding free energies served as a basisto bind TAR, 43 were assayed for inhibition of the
for developing a more accurate screen for ligand bindingTat-TAR interaction via electrophoretic mobility shift
to RNA.assays. Eleven compounds (between 0.1 and 1 M)
Acquired immunodeficiency syndrome (AIDS) is causedinhibited the Tat-TAR interaction, and some inhibited
by the human immunodeficiency virus, type 1 (HIV-1).Tat transactivation in cells. NMR spectra verified spe-
Unique structures on the HIV-1 RNA genome play essen-cific binding to the 5 bulge and no interaction with
tial roles in viral replication and are good targets forother regions of TAR.
drug design. One such site is the transactivation re-
sponse (TAR) element. It binds the viral transactivation
Introduction protein, Tat. Both form a ternary complex with human
cyclin T1 (CycT1), resulting in increased rates of elonga-
Ribonucleic acids are a promising, yet relatively un- tion of transcription on the HIV-1 genome [7]. TAR RNA
tapped, target for drug design. Currently, most drugs forms a short, bulged stem-loop structure (Figure 1) at
on the market target proteins [1]. Yet, in many ways the 5 end of all viral transcripts [8]. Essential features
RNA may be a better target than a protein because it is of Tat and TAR have been delineated. In particular, the
upstream in the translation pathway. Inhibiting a single 5 bulge and adjacent stem region are critical for Tat
RNA molecule could prevent the production of thou- binding (critical residues are highlighted in red in Figure
sands of proteins. As more three-dimensional (3D) RNA 1) [9, 10]. Interrupting the interaction between Tat and TAR
structures become available, unique binding sites will blocks HIV-1 replication in infected cells [11].
be defined for targeting. There have been efforts to find small organic inhibi-
There have been some attempts to discover drugs tors of the HIV-1 Tat-TAR interaction [12]. Analogs of
that interact with RNA [2, 3]. These have focused primar- amino acids or nucleotides [13, 14] and aminoglycosides
ily on antibacterial agents because the target of some [15] can inhibit the binding of Tat to TAR. Aminoglyco-
clinically important antibacterial drugs, originally dis- side-arginine conjugates were effective inhibitors of the
covered by soil sample screening, was found to be bac- Tat-TAR interaction [16]. Whereas the best of the other
terial RNA. In general, these aminoglycosides are valu- compounds bind with micromolar affinity, some aminogly-
able [1], but they have undesirable features: they interact cosides that were conjugated with multiple arginines
with other sites on nucleic acids in human cells, and achieved binding in the 20–400 nM range.
bacteria develop resistance. Consequently, it is desir- In this report, we first describe the generation of an
able to identify new classes of compounds for drug improved scoring function, which is essential for compu-
development and RNA targets that cannot be altered tational ligand screening of RNA targets. This virtual
because of function. In humans, where RNA is ex- screening methodology should lead to faster and less
pressed at even higher levels, drug candidates must be expensive drug discovery. Next, we describe how we
specific for a single RNA site. found new classes of ligands that block the Tat-TAR
In recent years, several drugs designed by the use of interaction. Virtual screening of the ACD identified possi-
ble candidates, in vitro electrophoretic mobility shift
assays (EMSA) and NMR spectra demonstrated that5 Correspondence: james@picasso.ucsf.edu
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simplified. Consequently, we developed an empirical
scoring function for use in ranking compounds after
docking created all of the ligand-RNA complexes [19].
The determination of several RNA-ligand complex
structures has advanced understanding of interactions
between RNA and ligand [20–33]. Binding affinities for
these complexes were also reported [26, 27, 34–42].
We used these structures and binding energies first to
develop a scoring function and subsequently to validate
our procedure. These 13 RNA-ligand complexes with
known structures and binding affinities include three
different neomycin-RNA complexes and two separate
tobramycin-RNA aptamers and are listed in Table 1. In
addition, data for binding and nonbinding analogs of
several RNA complexes were included in the calcula-
tions. For our computational methods, it is important
that structures and binding energies of known test cases
be reproduced. After several exploratory calculations
to reproduce the structures of the known RNA-ligand
complexes, we utilized the procedure described in the
Experimental Procedures section.
Rigid redocking (RMSD 1 A˚) accurately reproduced
all 13 complexes (Table 1). The most accurate prediction
of binding orientation was achieved when the electro-
static interactions were reduced by two; default values
overemphasize the electronegative phosphate back-Figure 1. TAR RNA Secondary Structure
bone. By reducing charged interactions (equivalent toResidues shown in red are critical for binding of the Tat protein.
salt condensation around the backbone [43]), we were
able to recreate the original binding orientations. With
flexible “anchor-and-grow” docking, arginine, citrullene,they bind specifically to the Tat binding site on TAR,
and the aminoglycosides did not bind in their originaland a functional assay showed that they inhibit Tat
positions; other conformations had good DOCK scores.transactivation in cells.
In part, this is a sampling issue because not all possible
binding conformations were tried. With a large database,
Results exhaustive sampling would be too time consuming.
Also, this may reflect lack of a solvation term in the
Basic Screening Rationale DOCK scoring function. Alternate conformations scored
We have previously described the basic rationale of well in DOCK but could become disfavored if solvation
our approach to discovering novel ligands capable of were considered.
binding to unique 3D RNA structures [5, 6]. After select- When the ligands were reminimized with ICM, they
ing a promising target with available 3D structure, we maintained their original docked conformation. Impos-
perform virtual screening of the ACD, which contains ing light constraints sufficed to keep the original DOCK
181,000 compounds, to identify candidates with good position. Because DOCK does not accurately predict
predicted affinity for this RNA target. true binding affinity, this is essential for determining an
Two different programs were used for docking the accurate scoring value for the complex resulting from
ligands to the target RNA: DOCK [17] and ICM [18]. DOCK.
DOCK is fast for matching compounds to a specific site After ICM reminimization, interaction energies for the
on a target molecule. It accommodates rigid and flexible ligand-RNA complex were decomposed into electro-
ligands and utilizes a relatively simple scoring function static, van der Waals, hydrogen bond, solvation, and
that evaluates van der Waals (VDW) and electrostatic entropic contributions from rotatable bonds [5]. The
interactions. The number of compounds in the ACD re- binding free energy is approximated as the sum of these
quires rapid docking and simple scoring. After DOCK terms:
runs,20% of the ACD compounds ranked well enough
for subsequent ICM screening. ICM is a more diverse Gbind  A · EVDW B · EEl C · EHbond
scripting program that allows rapid exploration of con-
 D · Esolv 0.3 · Etors (1)formational space via Monte Carlo searches using inter-
nal coordinates. ICM also permits flexible receptors and For each E term, the energies of the free RNA and free
includes terms for hydrogen bonding and solvation. ligand were subtracted from the energy of the complex.
Linear regression analysis using data for the thirteen
known ligand-RNA complexes yielded values for coeffi-Scoring Function for Ligand Binding to RNA
It is crucial to assess the relative binding strength of cients A, B, C, and D for VDW, electrostatic, H bond, and
solvation terms, respectively. Known binding energiesscreened compounds. Potential energy functions (force
fields) used during the docking process are necessarily were reproduced, but manual adjustment was carried
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Table 1. RNA-Ligand Complexes with 3D Structure and Binding Constant Available
PDB Entry Name Kd (M) G (kcal/mol)
1RAW [22] AMP-RNA aptamer 2–14 [34] 6.95
1KOC [23] Arginine-RNA aptamer 60 [35] 5.76
1F27 [24] Biotin-RNA aptamer 6 [36] 7.12
1KOD [23] Citrullene-RNA aptamer 68 [35] 5.68
1FMN [25] FMN-RNA aptamer 0.5–200 [37] 6
1BYJ [26] Gentamicin-16S rRNA 0.01 [26] 10.98
1EI2 [27] Neomycin-TAU exon RNA 1 [27] 8
1NEM [33] Neomycin-RNA aptamer 0.1 [38] 9.6
1QD3 [29] Neomycin-TAR 1 [39] 8
1PBR [30] Paromomicin-16S rRNA 0.2 [40] 9.19
1EHT [31] Theophylline-RNA aptamer 0.4 [41] 8.72
1TOB [28] Tobramicin-RNA aptamer 0.0007 [42] 12.48
2TOB [32] Tobramicin-RNA aptamer 0.0012 [42] 12.24
out to improve the separation of known binders from ence experimental structure.) Importantly, the ranking
of each ligand improved compared to the initial DOCK“non-binders.” Values that were ultimately used were
A  0.15, B  0.1, C  0.5, and D  0.025 for the full ranking. Complete results of the fitness test are accessi-
ble at http://picasso.ucsf.edu.force field. These values reflect both binding and non-
binding ligands scoring properly. Any ligand that experi-
mentally does not bind its RNA should have a “poor” Database Screening against TAR
We used our database screening procedure, as de-binding free energy (0). Thus, while improving scoring
of known non-binders, the final scoring function yields scribed in the Experimental Procedures section and
shown as a schematic in Figure 2, to find among thesignificant error in the predicted binding energy of
known ligands (Table 2). Individual energy terms are 181,000 compounds in the ACD several lead com-
pounds that could bind to the 5 bulge on TAR. A list ofwell balanced. Ligands that bind through electrostatic
interactions (e.g., aminoglycosides) show this prefer- 500 compounds, all predicted to bind with high affinity
to TAR, was generated. These compounds are diverseence, whereas those in stacking interactions (e.g., the-
ophylline) predominantly have VDW contacts. and share no common structural features. They possess
aromatic moieties that interact with the bases, chargedAs a final test of the scoring function, each RNA struc-
ture was screened against a small database (175 com- groups that bind to the phosphates, and H bond donors
and acceptors that form other specific interactions. Thepounds) that included all native ligands and 150 other
randomly chosen compounds. The scoring procedure only common “feature” appears to be size and shape;
all compounds fit tightly into the 5 bulge.worked well for selecting the native ligand for each RNA
target. This validation ensured that true binders ranked Arginine binds weakly to TAR (Kd1 mM), and three
arginine analogs are in the final list of 500 compounds.high in our final list. For arginine and citrullene aptamers,
the binding conformation of the ligand was not predicted The highest ranking (	-napthyl-arg) is at position 87,
with a score of4.38 kcal/mol. Several arginine analogsvery well, but predicted and experimental binding ener-
gies were relatively close. Residual differences were due with aromatic groups are present in the ACD. Aromatic
groups add favorable stacking interactions that are notto sampling with ICM. (When developing the scoring
function, we did not allow the receptor to move so that present with arginine alone. Aminoglycosides also bind
TAR but do not appear in the final 500; most are largewe could approximate the binding energy for the refer-
Table 2. Binding Affinities (kcal/mole) of Native Ligands Used for Parameterization of Scoring Function
PDB Entry G  RT ln Kd Predicted Scorea Difference
1RAW (AMP) 6.95 3.8 3.2
1KOC (Arg) 5.76 3.0 2.8
1F27 (Biotin) 7.12 4.5 2.6
1KOD (Cit) 5.68 3.2 2.4
1FMN (FMN) 6 3.9 2.1
1BYJ (Gent) 10.98 8.9 2.1
1EI2 (Neo 1) 8 6.0 2.0
1NEM (Neo 2) 9.6 13.0 3.4
1QD3 (Neo 3) 8 11.2 3.2
1PBR (Par) 9.19 8.7 0.5
1EHT (Theo) 8.72 6.5 2.2
1TOB (Tob 1) 12.48 11.3 1.2
2TOB (Tob 2) 12.24 11.7 0.5
a Predicted binding free energy (kcal/mol) for native ligands based on scoring function in Equation 1.
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Figure 3. Electrophoretic Mobility Shift Assay for Monitoring Inhibi-
tion of the Interaction of Tat with TAR in the Presence of CycT1
Binding among CycT1, Tat, and TAR can be disrupted by some
phenothiazines. Equimolar concentrations (0.1 M) of radiolabeled
TAR and the hybrid CycT1-Tat protein were incubated alone or with
decreasing concentrations of different compounds and separated
by nondenaturing gel electrophoresis. Data with prochlorperazine,
chlorpromazine, and acetylpromazine are presented. Numbers refer
to the concentration of these compounds in M. CycT1-Tat fusion
protein was present in lanes 2–14. Free probe is presented in laneFigure 2. Flow for Computational Screening of a Chemical Data-
1. Arrows point to the RNA-protein complex between CycT1-Tatbase, e.g., the Available Chemicals Directory
and TAR and to free TAR.The number of compounds, after scoring and ranking, that are
passed along to the subsequent stage is shown to the right.
Three phenothiazines (prochlorperazine, chlorproma-
zine, and acetopromazine) each inhibited the Tat-TAR in-
and thus are filtered out by the Lipinski rules [44]. Also,
teraction at all concentrations examined (Figure 3, lanes
the 5 bulge structure does not permit entry of aminogly-
3–6, 8–10, and 12 and 13, respectively), but trifluopera-
cosides; large structural rearrangements would be nec-
zine and thioethylperazine did not (our unpublished
essary. Our method permits some flexibility of RNA in
data). These phenothiazines are used clinically as anti-
the final stages of calculation, but it is still rather limited.
psychotic, sedative, and antiemetic agents. Recent stud-
Previous studies showed a rearrangement of the 5
ies also suggest that they have antibiotic properties [45].
bulge upon neomycin binding [29].
Figure 4 presents the compounds that inhibit at con-
For the screening in vitro, we purchased 50 of the top
centrations of 0.1–1 M. Two are fluorescein analogs,
200 compounds on the final list. Some of the leads on
another appears to be an intercalator, and the others
the list were eliminated based on chemical intuition that
have pharmaceutical potential. The EMSA data clearly
they would not be good drugs, high cost (at least for
support the computational screening results. Although
our lab), and apparent lack of availability (in spite of the
some compounds bind, modifying these ligands could
ACD listing). After assaying these, we purchased four
yield even better inhibitors.
more phenothiazines.
Functional Assays in Cells
We studied some compounds in cells. ProchlorperazineRNA Binding Assays In Vitro (Electrophoretic
Mobility Shift Assay) results are shown in Figure 5. We cotransfected target
and effector plasmids in the presence of prochlorpera-EMSA is an effective method for determining whether
TAR forms a complex with Tat and human cyclin T1 [7]. zine in HeLa cells. Two different sets of targets and
effectors were used. First, HIV-1 LTR and Tat were coex-In the presence of TAR, containing the 5 bulge and
central loop, and these proteins, a lower mobility com- pressed. Second, as a control, we utilized the heterolo-
gous tethering system of the Regulator of Expressionplex is observed on polyacrylamide gels (Figure 2, lanes
1 and 2). The lack of higher-order complex formation of Virion genes (Rev) and its Rev response element (RRE)
RNA. If specific, our compounds should block Tat trans-signifies that a compound can block this RNA-protein
interaction. Indeed, of the 50 compounds, eight were activation via TAR and not have any effects on the heter-
ologous tethering of the RevTat fusion protein via RRE.found to completely prevent the binding between Tat
and TAR at concentrations between 0.1 and 1 M, with Indeed, at concentrations between 5 and 20 M, pro-
chlorperazine inhibited Tat transactivation up to 6-foldhybrid CycT1-Tat protein and TAR concentrations each
at 0.1 M. Three others partially inhibited at 1 M (data (Figure 5, bars 2 and 5) in a dose-dependent fashion.
Importantly, this compound had no effect on the hybridnot shown). Prochlorperazine was one of the best inhibi-
tors, so four analogs were also purchased and assayed. RevTat protein on the RRE (Figure 5, bars 7 and 10). With
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Figure 5. CAT Assay Results Designed to Test Whether or Not Pro-
chlorperazine, Which Inhibits the Tat-TAR Interaction, Can Inhibit
Tat Transactivation in Cells
Tat transactivation is clearly inhibited by prochlorperazine in cells.
HeLa cells coexpressed either HIV-1 LTR (TAR) and Tat or pRRESCAT
(RRE) and the RevTat fusion protein. Increasing concentrations of
prochlorperazine diminished Tat transactivation via TAR but, as a
control, had no effect on that between Rev and RRE. As observed
in lanes 2 and 5, Tat transactivation was equivalent in native and
heterologous RNS-tethering systems. The data represent three ex-
periments with depicted standard errors. Expression levels from
both target plasmids were set to one (lanes 1 and 6).
especially when differences were due to TAR-ligand
complex formation.
NMR experiments with several lead compounds con-
firmed binding to the 5 bulge of TAR. In particular,
chlorpromazine and its relatives produced very distinct
chemical shifts for resonances emanating from bulge
residues. For example, the 5 bulge contains three py-
Figure 4. Ligands Found Experimentally to Bind to the TAR 5 Bulge rimidine residues (U23, C24, and U25) that can be moni-
Ligands found to bind (G6 kcal) to the TAR 5 bulge at concen- tored by their H5-H6 crosspeaks in 2D TOCSY spectra.
trations of 1 M or less as determined by EMSA. Binding free ener-
NMR experiments confirmed acetylpromazine bindinggies (kcal/mole) predicted by Equation 1 are in parentheses.
to TAR. Most satisfying, chemical shifts changed upon
the addition of ligand only for nuclei in the 5 bulge and
not in the stem or loop. Figure 6A illustrates this withprochlorperazine 20 M, significant cellular toxicity
resulted. In short, some compounds specifically inhibit pyrimidine H5–H6 crosspeaks. A comparison of chemi-
cal shifts with and without acetylpromazine revealedthe interaction among CycT1, Tat and TAR, and trans-
activation in cells. the following substantial (0.1 ppm) changes (downfield
and upfield shifts are denoted by positive and negative
values, in ppm, respectively): A22H8 (0.12), A22H4NMR Screening of Selected Compounds
With structure-based drug discovery, lead compounds (0.14), U23H6 (0.16), U23H5 (0.22), U23H1 (0.14),
U23H2 (0.13), U23H4 (0.15), C24H1 (0.10), U25H2identified by virtual screening are almost always aimed
at the active site of the protein or nucleic-acid target. (0.11), U25H3 (0.17), G26H1 (0.22), C39H1 (0.13),
C39H3 (0.15), U40H6 (0.11), U40H5 (0.10), U40H1Compounds identified by virtual screening bind a spe-
cific target. In vitro assays confirm inhibition but do not (0.18), C41H6 (0.12), and C41H5 (0.13). All chemi-
cal-shift changes were observed for nuclei in the bulgeexplicitly show that the ligand binds to the designated
site, and they do not preclude its binding to other sites. residues U23, C24, U25 and adjacent base-pairs (A22,
G26, C39, U40, and C41). Even with a 5-fold excess ofHowever, NMR not only shows whether a ligand binds
to the specific target but also reveals all sites on the acetylpromazine, no chemical-shift changes were de-
tected from nuclei in other regions of TAR. The chemical-target that interact with the ligand. This requires nuclear
resonance assignments for the target. We saved sub- shift data show that the binding of acetylpromazine to
TAR is specific to the 5 bulge. Nonspecific ligand-RNAstantial time by using resonance assignments that Prof.
Jamie Williamson sent to us for HIV-1 TAR. His lab has interactions are not involved in the binding.
The bulge region contains several uridine residues,revealed valuable insights into interactions between
peptides derived from Tat and TAR [46, 47]. We primarily so a sample with only U residues uniformly labeled in
13C and 15N was prepared. Figure 6B shows the riboseneeded to reconcile our spectra with those assignments,
Chemistry & Biology
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Figure 6. NMR Experiments Show that Acetylpromazine Binds Specifically to the 5 Bulge of TAR and Not to the Stem or Loop Regions
(A) 2D TOCSY spectrum showing pyrimidine H5-H6 crosspeaks for TAR. Red: free RNA; blue: complex with acetylpromazine. Conditions: 1.5
mM RNA, 20 mM phosphate, 20 mM NaCl (pH 6.5), 35
C. Green arrows indicate chemical-shift changes.
(B) Ribose H1-H2 region of the HCCH-COSY spectrum for {13C,15N-labeled U}TAR in the absence (red) and presence (blue) of acetylpromazine.
Arrows identify crosspeaks that shift with added ligand.
H1-H2 region of HCCH-COSY spectra for the {13C,15N- ticular better treatment of solvation effects with the gen-
eralized Born or Poisson-Boltzmann approaches inlabeled U} TAR in the absence and presence of acetyl-
promazine. The HCCH-COSY spectral data confirm the DOCK and ICM, should improve selection. Develop-
ments permitting greater flexibility in the RNA targetconclusions from TOCSY spectra, and both confirm the
computational as well as in vitro and in vivo assay re- would also help.
We identified acetylpromazine as an exciting leadsults, showing that the compounds bind in a specific
manner to this RNA. In particular, NMR chemical shifts compound that binds specifically to the same TAR site
that is recognized by the Tat protein. Determination ofare observed only for residues A22, U23, C24, U25, G26,
C39, U40, and C41 (see Figure 1 to observe how these the structure of this complex is progressing. This could
allow us to suggest modifications designed to enhanceresidues define the binding site).
affinity and specificity for the 5 bulge. The structure can
also be compared to computational predictions to improveDiscussion
our scoring function. With few RNA-ligand structures
currently available, each additional one could greatlyThe computational screening of compounds for binding
improve our ability to make predictions for drug dis-to 3D protein structures has led to clinically useful drugs
covery.[4]. Typically, initial screens found weak (10–100 M)
binders that could be modified to yield nanomolar bind-
ing compounds—the improvement in ligand affinity Significance
needed is equivalent to the energy involved in forming
a couple of additional hydrogen bonds. This combina- The computational screening of compounds that bind
to three-dimensional protein structures has led to sev-tion of computational and chemical optimization ap-
proaches has been quite successful in moving com- eral novel, clinically useful drugs [4]. Typically, these
initial screens identified weak (10–100 M) binderspounds into clinical trials.
We have developed a computational method that pre- that could be modified to yield nanomolar binding
compounds—the needed improvement in ligand affin-dicts the binding of small molecules to RNA targets.
Critical to our success, the scoring function was opti- ity is equivalent to the energy involved in forming a
couple of additional hydrogen bonds. The combinationmized to produce approximate free-energy scores as
well as relative ranks. The fact that ten of our approxi- of computational lead generation and chemical opti-
mization has been quite successful in moving com-mately 50 selected compounds, at concentrations of
0.1–1 M, inhibited the binding between TAR and Tat pounds into clinical trials. Other than initial work from
the University of California-San Francisco, there hasshows satisfactorily that the scoring function worked
well. It is even more encouraging that the compounds been no report of the computational targeting of RNA.
Here we have demonstrated the concept with a proto-are specific for the unique 5 bulge in TAR. However,
the 40 false positives show that improvements are col that predicts the binding of small molecules to
RNA targets. Developing an effective scoring functionneeded. Future changes to the scoring function, in par-
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charge between 5 and 5, and a maximum of 20 rotatable bonds.to assess the binding of these compounds to RNA has
The resulting 128,000 drug-like compounds were screened withbeen of paramount importance. We have optimized
DOCK. Each compound was permitted 500 rigid orientations. Energythis scoring function to produce both approximate
scoring was used, with a distance-dependent dielectric of 4 r. In
binding free energies and relative ranks. The resulting addition, electrostatic interactions were reduced by a factor of two
candidates are non-peptide, non-nucleotide organic based on results we obtained with the small database screening.
The top 30,000 compounds were kept.compounds whose molecular weight is generally less
Subsequently, ICM was used in three sequential steps to refinethan 600 Da. Although the method is far from perfect
the initial DOCK results. First, each of the 30,000 compounds re-and there is room for improvement, our initial results
sulting from the DOCK search was reminimized and scored withwith HIV-1 TAR as a target are very encouraging. We
500 Monte Carlo and 50 minimization steps. The scoring function
have identified promising drug candidate leads that (Equation 1) was used to reorder the original DOCK list. Next, the
inhibit the crucial Tat-TAR interaction, according to top-scoring 5000 compounds were permitted flexibility in a longer
calculation with 5000 Monte Carlo and 500 minimization steps, withan in vitro assay, at a concentration of 0.1–1 M.
rescoring. Finally, RNA residues within 5 A˚ of the binding pocket,NMR spectra of TAR complexed with one promising
as well as the ligand, were allowed to move during the Monte Carlolead, acetylpromazine, demonstrate that the com-
search. The 500 highest ranking compounds that result are all pre-pounds bind to the targeted bulge site on TAR and do
dicted to bind with high affinity to the 5 bulge site.
not bind to the stem or loop regions. Furthermore,
we have shown that some of them also inhibit Tat
Preparation of TAR RNA
transactivation in cells. Optimization of these com- Samples of the 31 nucleotide TAR (Figure 1) were prepared by in
pounds to enhance their affinity and decrease their vitro transcription with T7 RNA polymerase and a synthetic DNA
template [49]. Most preparations yielded unlabeled TAR, but TARside effects will lead to a new class of chemical agents
13C,15N-labeled only at U residues was prepared by the use of labeledfor inhibiting the HIV virus.
UTP (Isotec).
Experimental Procedures
In vitro Electrophoretic Mobility Shift Assay (EMSA)
To assess whether compounds selected by computational methodsComputational Screening with DOCK
actually bind to the 5 bulge of TAR, an in vitro EMSA assay wasA flow diagram showing our virtual screening procedure that works
developed [7]. Fifty compounds were selected from the final list ofwell for targeting RNA structures is shown in Figure 2. The DOCK
500 (vide supra) and ordered. Each compound was dissolved to 10program was utilized for the initial screening of ligands [17]. First,
M in DMSO and incubated with 32P-radiolabeled TAR (1 M) forthe known binding sites were filled with sphere sets from the
20 minutes at 30
C in EMSA binding buffer (30 mM Tris-HCl [pHSPHEREGEN module of DOCK. Rigid redocking of the ligands with
8.0]/70 mM KCl/0.01% Nonidet P-40/5.5 mM MgCl2/1 mM DTT/13%DOCK was then employed to reproduce the bound conformation in
glycerol), and poly-dIdC and poly-rIrC blockers. A hybrid protein500 orientation steps with energy (electrostatic and VDW) scoring.
composed of Tat and CycT1 was added with incubation for 20 minDifferent scaling factors for both the electrostatic and VDW terms
at 37
C. The final concentrations of hybrid Tat-CycT1 and TAR werewere tested for their ability to predict the correct structure. For
0.104 mM and 0.10 mM, respectively. The mixture was loaded ontocomparison, flexible docking via the “anchor-and-grow” method
a 6% nondenaturing SDS gel; electrophoretic power was 4 W for 3was also used for the production of binding conformations [48].
hr at 4
C. The gel was dried, and autoradiography exposed positions
of the TAR and Tat-CycT1:TAR complex on the gel.Development of the Scoring Function
The ICM program [18] was used to explore ligand binding in more
Chloramphenicol Acetyl Transferase (CAT) Assaydetail for a subset of structures that scored well in binding to RNA
HeLa cells were preincubated with drug in concentrations rangingvia DOCK. Once binding orientations were determined with DOCK,
from 0.01 to 10 M. DNA constructs containing the engineered CATICM was used to determine a binding score. The docked conforma-
gene preceded by TAR or RRE promoters were transfected into thetion was tethered to its original position with light (0.1 kcal/mol/A˚2)
HeLa cells with Lipofectin. Cells were incubated at 37
C, 5% CO2constraints and subjected to 5000 Monte Carlo search steps with
for 5 hr. Cells were rinsed, fresh drug and media (3 ml 10% Fetal500 minimization steps. This maintains the binding conformation
Calf Serum, DMEM) were added, and then the cells were incubatedand adjusts for slight variations between the DOCK and ICM force
for 3 days at 37
C, 5% CO2. Cells were collected by rinsing with 1fields. In particular, small differences in VDW calculations can lead
l phosphate buffer and centrifugation for 4 min at 4000 rpm. Lysisto large differences in scores if the ligands are not allowed to repo-
buffer was added to the pellet, and centrifugation for 10 min atsition.
14,000 rpm followed. The supernatant was heated to 65
C for 5 minTo test the scoring function, each RNA target was screened
(to remove background protein expression) and centrifuged for 10against a small database of compounds (all native ligands plus150
min at 14,000 rpm. 100 l supernatant, 1 mg chloramphenicol, 1 grandom compounds). With ICM rescoring, a two-step approach was
3H-acetyl-CoA, and EconoFluor solution were mixed and immedi-used. First, the ligand was tethered with 0.1 kcal/mol/A˚2 constraints
ately placed into the scintillation counter. We measured CAT enzymefor 500 Monte Carlo steps with 50 minimization steps. Next, both
activity by detecting the amount of 3H-acetyl-chloramphenicol.the ligand and RNA residues within 5 A˚ were free to move for 5000
Monte Carlo steps (with 500 minimization steps). The same proce-
dure was used subsequently for large database screening. NMR Screening of Selected Compounds
All NMR spectra were acquired on Varian Inova 600 MHz spectrome-
ters, processed with NMRpipe [50], and analyzed with SPARKY [51].Database Screening against TAR RNA
The 181,000 compounds in the Available Chemicals Directory, 1998 Typical sample conditions were 1–1.5 mM RNA in 20 mM sodium
phosphate buffer and 20 mM NaCl (pH 6.5). Each compound wasversion, (MDL Information Systems) were scanned to detect lead
compounds. in 2-fold excess over RNA. 2D TOCSY spectra were collected in 2.5
hr at 35
C in D2O with 60 ms mixing time, MLEV-17 mixing sequence,The HIV-1 TAR target site (the bulge and adjacent base pairs in
Figure 1) was built from a model of BIV TAR [5]. The 181,000 com- 512 FIDs of 4096 complex points, and a 6000 Hz spectral width in
both dimensions. The phase-sensitive mode in the indirectly de-pounds in the ACD were scanned to detect lead compounds as
follows. Initially, a simple filter eliminated “non-drug-like” molecules, tected dimension was achieved by the TPPI method [52]. The 2D
(1H, 1H) HCCH-COSY spectrum was collected for TAR 13C, 15N-labeledbased on rules outlined by Lipinski [44]. For our situation, requisite
ligand characteristics were a maximum molecular weight of 600, a only at U residues. Coupling constants were optimized for ribose
with JHC  165 Hz and JCC  40 Hz. Spectral widths were 2200maximum total of ten hydrogen bond donors or acceptors, a formal
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Hz in both 1H dimensions. 512 FIDs of 2048 complex points were inhibition of human immunodeficiency virus type-1 transactiva-
tion. J. Virol. 65, 6811–6816.collected.
14. Hamy, F., Brondani, V., Flo¨rsheimer, A., Stark, W., Blommers,
M.J.J., and Klimkait, T. (1998). A new class of HIV-1 Tat antago-Supplemental Material
nist acting through Tat-TAR inhibition. Biochemistry 37, 5086–A supplemental table is available at http://picasso.ucsf.edu. This
5095.table shows the predicted binding affinities and relative rank of
15. Zapp, M.L., Stern, S., and Green, M.R. (1993). Small moleculesnative ligands with their RNA targets. The data were obtained with
that selectively block RNA binding of HIV-1 Rev protein inhibitthe computational screening procedure described in the Experimen-
Rev function and viral production. Cell 74, 969–978.tal procedures.
16. Litovchick, A., Evdokimov, A.G., and Lapidot, A. (2000). Amino-
glycoside-arginine conjugates that bind TAR RNA: synthesis,Acknowledgments
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